Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A class of compounds extracted from Chrysanthemum chrysanthemum, its pharmaceutical composition and its application in preventing and treating neurodegenerative diseases

A neurodegenerative and compound technology, applied in the field of medicine, can solve the problems such as the patent documents of the preparation method of the monomeric compound of chrysanthemum in the neuron cell, and the traditional Chinese medicine chrysanthemum, so as to prevent and treat neurodegenerative diseases, strengthen the Total Antioxidant Capacity, Structural Novel Effect

Active Publication Date: 2021-01-12
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no research report on the use of the traditional Chinese medicine Hangbaiju in the treatment of Parkinson's and Alzheimer's disease, and there is no patent document on the preparation method of the compound monomer of Hangbaiju with neuron cell protection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A class of compounds extracted from Chrysanthemum chrysanthemum, its pharmaceutical composition and its application in preventing and treating neurodegenerative diseases
  • A class of compounds extracted from Chrysanthemum chrysanthemum, its pharmaceutical composition and its application in preventing and treating neurodegenerative diseases
  • A class of compounds extracted from Chrysanthemum chrysanthemum, its pharmaceutical composition and its application in preventing and treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0023] Example Chrysanthemumic acid A~C (compound 1-3) preparation and identification of Chrysanthemum monomeric compound Chrysanthemumic acid A~C (compound 1-3) 10kg Chrysanthemum medicinal material is extracted 3 times by reflux of 70% ethanol, each time 2 hours, use petroleum ether, chloroform, Ethyl acetate and n-butanol were extracted three times in sequence, the n-butanol part was recovered as solvent, dispersed and dissolved with distilled water, the supernatant was passed through D101 macroporous adsorption resin, eluted with ethanol / water solvent system, and the 70% ethanol eluted part was collected After recovering the solvent, the above compounds Chrysanthemumic acid A (55 mg), Chrysanthemumic acid B (35 mg), and Chrysanthemumic acid C (67 mg) were obtained through repeated purification by gel column chromatography and reverse-phase silica gel column chromatography. After UV, IR, NMR, Its structure was identified by means of spectroscopy such as MS and CD, and it was...

experiment example 1

[0029] Experimental Example 1 Protective effect of Chrysanthemumic acid A~C, Chrysanthemum compound, on SH-SY5Y cells damaged by hydrogen peroxide

[0030] SH-SY5Y cells were cultured in DMEM containing 10% fetal bovine serum (FBS), 100 U / mL penicillin and streptomycin based on 5% CO 2 , cultured in a 37°C incubator. After the cells were 80% confluent, they were subcultured at 1×10 4 cells / mL density, 100 μL per well was inoculated in a 96-well plate overnight. Treat with 10 μM Chrysanthemumic acid A (1), Chrysanthemumic acid B (2), and Chrysanthemumic acid C (3), and replace with 100 μL containing H 2 o2 fresh solution, and continued to incubate for 24 h. Afterwards, 10 μL of MTT (5 mg / mL) was added to each well, and the incubation was continued for 4 h. Discard the medium in the 96-well plate by flipping, add 150 μL of DMSO solution to each well, shake at 37°C for 15 minutes to fully dissolve the crystals, detect the OD value of each well at 570 nm on a microplate reader...

experiment example 2

[0034] Experimental example 2 Chrysanthemumic acid A~C (compound 1-3) monomer compound Chrysanthemumic acid A~C (compound 1-3) scavenging ability of DPPH free radical

[0035] Dispense 10 μL of 2 x 10 -4 Compound M samples were added to a 96-well plate, and then 190 μL of 200 μmol / L DPPH in absolute ethanol was added, reacted at 37° C. in the dark for 30 minutes, and the absorbance was measured at 517 nm. The ability to scavenge free radicals uses Sc (%)=(1-A sample / A control)×100%. The control is the absorbance value of the solution without adding the sample after the reaction.

[0036] As shown in Table 2, compounds Chrysanthemumic acid A~C all have strong scavenging effects on DPPH free radicals, and compound Chrysanthemumic acid A has a stronger ability to scavenge free radicals than the positive control drug Vitamin C.

[0037] Table 2: Results of compounds' ability to scavenge DPPH free radicals

[0038]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel-structure compound extracted from chrysanthemum morifolium, a preparation method of the compound and application of the pharmaceutical composition in the preparation of drugs for preventing and treating neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease. Pharmacological experiments prove that the compound is capable of effectivelyinhibiting hydrogen peroxide induced neuron damage, simultaneously has relatively strong DPPH free radical scavenging capacity, good resistance to Parkinson's disease and Alzheimer's disease and can be used for preparing the drugs for preventing and treating Parkinson's disease and Alzheimer's disease.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a compound of chrysanthemum chrysanthemum isolated from traditional Chinese medicine chrysanthemum chrysanthemum and its application in preventing and treating neurodegenerative diseases. Background technique [0002] Parkinson's disease (PD) is the most common neurodegenerative disease characterized by motor dysfunction. The incidence rate of people over 65 years old is 1%. There are about 1.7 million Parkinson's patients in my country. The incidence of the disease increases sharply with age, and the population aging increases, and the number of patients will also show an upward trend year by year. PD is a serious threat to human health, not only brings great pain to patients, but also creates a heavy burden on families and society. At present, there is no effective treatment for the disease, and the commonly used levodopa replacement therapy can only last for about 5 years....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/08A61K31/35A61P25/16A61P25/28A61P9/10
CPCC07D493/08
Inventor 张培成王晓良杨鹏飞彭英杨桠楠王珊冯子明姜建双
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com